The Drug-Induced Respiratory Disease Website and App

Status post-hematopoietic stem cell (HSCT) or bone marrow transplantation (BMT)

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XIX.br

Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

Publications

Takeuchi Y, Miyagawa-Hayashino A, Chen F, Kubo T, Handa T, Date H, Haga H

Pleuroparenchymal fibroelastosis and non-specific interstitial pneumonia: frequent pulmonary sequelae of haematopoietic stem cell transplantation.

Histopathology 2015 Mar;66;536-44 — 2015 Mar — 536-44

Fujikura Y, Kanoh S, Kouzaki Y, Hara Y, Matsubara O, Kawana A

Pleuroparenchymal fibroelastosis as a series of airway complications associated with chronic graft-versus-host disease following allogeneic bone marrow transplantation.

Internal medicine (Tokyo, Japan) 2014;53;43-6 — 2014 — 43-6

Parish JM, Muhm JR, Leslie KO

Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.

Mayo Clinic proceedings 2003 May;78;630-4 — 2003 May — 630-4